Literature DB >> 18567869

CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis.

Bianca M Conti-Fine1, Monica Milani, Wei Wang.   

Abstract

Although human and experimental acquired myasthenia gravis (MG) are prototypic antibody (Ab)-mediated autoimmune diseases, synthesis of the pathogenic anti-acetylcholine receptor (AChR) Abs, which are high affinity IgG, requires intervention of CD4(+) T helper cells and their cytokines. Moreover, cytokine signaling is crucial for development, modulation, and downregulation of immune responses, and therefore influences the initiation and evolution of the anti-AChR response in acquired MG. Cytokines are involved in the growth and differentiation of CD4(+) T cells, and are secreted by activated CD4(+) T cells as effectors of their functions: differentiated CD4(+) T cells are classified into subtypes based on the cytokines they synthesize and secrete. Because cytokines are synthesized by and act on a variety of cells and because they may influence the synthesis and/or the activity of other cytokines, the effects of their signaling, in both normal and autoimmune responses, are complex and sometimes even contrasting, depending on the circumstances when the cytokine action took place. In this chapter, we will review studies on the effects on the development of acquired MG symptoms of several cytokines secreted by activated CD4(+) T cells or influencing the activation of particular CD4(+) T cell subsets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18567869     DOI: 10.1196/annals.1405.042

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

1.  Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis.

Authors:  Y Li; V K Rauniyar; W F Yin; B Hu; S Ouyang; B Xiao; H Yang
Journal:  Neurol Sci       Date:  2013-05-26       Impact factor: 3.307

2.  Experimental autoimmune myasthenia gravis in the mouse.

Authors:  B Wu; E Goluszko; P Christadoss
Journal:  Curr Protoc Immunol       Date:  2001-05

Review 3.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

4.  Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  J Autoimmun       Date:  2014-01-02       Impact factor: 7.094

5.  Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.

Authors:  Yingkai Li; Jeffrey T Guptill; Melissa A Russo; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; James F Howard; Manisha Chopra; Weibin Liu; John S Yi
Journal:  Exp Neurol       Date:  2018-11-22       Impact factor: 5.330

6.  LncRNA LINC00680 Acts as a Competing Endogenous RNA and Is Associated With the Severity of Myasthennia Gravis.

Authors:  Li Liu; Huixue Zhang; Xiaoyu Lu; Lifang Li; Tianfeng Wang; Shuang Li; Xu Wang; Si Xu; Lei Li; Qian Li; Tingting Yi; Tao Wu; Zhimin Chen; Hongyu Gao; Jianjian Wang; Lihua Wang
Journal:  Front Neurol       Date:  2022-06-21       Impact factor: 4.086

7.  [Myasthenia gravis].

Authors:  J Schodrowski; M Seipelt; I Adibi-Sedeh; C Eienbröker; B Tackenberg
Journal:  Internist (Berl)       Date:  2016-04       Impact factor: 0.743

8.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

9.  MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1.

Authors:  Zhuoan Cheng; Shaobo Qiu; Lin Jiang; Anle Zhang; Wenjing Bao; Ping Liu; Jianwen Liu
Journal:  J Clin Immunol       Date:  2012-11-30       Impact factor: 8.317

10.  Rapamycin alleviates inflammation and muscle weakness, while altering the Treg/Th17 balance in a rat model of myasthenia gravis.

Authors:  Feng Jing; Fei Yang; Fang Cui; Zhaohui Chen; Li Ling; Xusheng Huang
Journal:  Biosci Rep       Date:  2017-07-16       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.